Related Experiment Video

Updated: Apr 6, 2026

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

15.4K

Antioxidant status and GST gene polymorphisms in antitubercular treatment-induced hepatotoxicity patients

S V Rana1,2, J K Kamboj3, S K Sharma4

  • 1Department of Super Specialty Gastroenterology, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh, India. svrana25@hotmail.com.

Hepatology International
|July 24, 2015
PubMed
Abstract

Insights

Antituberculosis treatment can cause liver damage. This study found increased oxidative stress and specific Glutathione S-transferase (GST) gene variations are linked to this hepatotoxicity, potentially identifying at-risk patients.

Area of Science:

  • Biochemistry
  • Genetics
  • Hepatology

Background:

  • Antituberculosis treatment (ATT) poses a risk of hepatotoxicity.
  • Glutathione S-transferase (GST) enzymes are crucial for detoxifying ATT metabolites.
  • Genetic variations in GST may influence susceptibility to ATT-induced liver injury.

Purpose of the Study:

  • To investigate the relationship between antioxidant status, oxidative stress, and GST gene polymorphisms in ATT-induced hepatotoxicity.
  • To identify potential biomarkers for predicting liver damage in patients undergoing ATT.

Main Methods:

  • Enrolled 250 tuberculosis patients undergoing ATT.
  • Assessed liver enzymes, oxidative stress markers, and antioxidant levels.
  • Genotyped GSTT1, GSTM1, and GSTP1 polymorphisms.

Main Results:

  • Patients with ATT-induced hepatotoxicity exhibited significantly higher oxidative stress.
  • GSTM1 gene presence was more common in patients with hepatotoxicity.
  • GSTT1 and combined GST1/M1 polymorphisms were less frequent in hepatotoxicity cases.

Conclusions:

  • Oxidative stress is associated with ATT-induced hepatotoxicity.
  • GST gene polymorphisms may play a role in the development of ATT-induced liver injury.
  • These findings could help identify individuals at higher risk for ATT-related hepatotoxicity.
Keywords:
Glutathione S-transferaseHepatotoxicityIsoniazidOxidative stress

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
IR-TEx: An Open Source Data Integration Tool for Big Data Transcriptomics Designed for the Malaria Vector Anopheles gambiae08:22

IR-TEx: An Open Source Data Integration Tool for Big Data Transcriptomics Designed for the Malaria Vector Anopheles gambiae

Published on: January 15, 2020

6.7K

Related Concept Videos

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
69
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
172
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation01:22

Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation

Glutathione, a tripeptide made up of glutamate, cysteine, and glycine, is a critical player in the detoxification of drugs and xenobiotics via a process known as glutathione conjugation or mercapturic acid formation. This phase II biotransformation reaction involves the covalent binding of glutathione to a drug or its metabolite, enhancing the compound's water solubility and enabling its excretion.
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
1.2K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K